Dissecting suppressor cell development

The development of a population of ‘regulatory’ immune cells is more complicated than originally thought, according to a paper to be published online this week in Nature Immunology.

PRESS RELEASE FROM NATURE IMMUNOLOGY

For papers that will be published online on 02 February 2007

This press release is copyrighted to Nature Immunology.

Warning: This document, and the Nature journal paper to which it refers, may contain information that is price sensitive (as legally defined, for example, in the UK Criminal Justice Act 1993 Part V) with respect to publicly quoted companies. Anyone dealing in securities using information contained in this document, or in advance copies of a Nature journal’s content, may be guilty of insider trading under the US Securities Exchange Act of 1934.

PLEASE CITE Nature IMMUNOLOGY AS THE SOURCE OF THE FOLLOWING ITEM. IF PUBLISHING ONLINE, PLEASE CARRY A HYPERLINK TO THE JOURNAL’S WEBSITE.

Dissecting suppressor cell development

DOI: 10.1038/ni1445

The development of a population of ‘regulatory’ immune cells is more complicated than originally thought, according to a paper to be published online this week in Nature Immunology. Regulatory T cells – Treg cells – suppress the activity of auto-aggressive immune cells and prevent the onset of catastrophic autoimmunity. Mice and humans expressing a mutant version of the protein Foxp3 contain few Treg cells and suffer from severe autoimmune pathology, suggesting that Foxp3 is essential for Treg cell development.

Talal Chatila and colleagues used a clever strategy to ‘track’ cells expressing a mutant version of the Foxp3 protein, and noted that although the cells were unable to suppress autoimmune activity as expected, they still developed many other typical Treg cell characteristics. The identity of another protein or proteins capable of driving these aspects of Treg cell development requires further investigation.

Author contact:
Talal A. Chatila (UCLA, Los Angeles, CA, USA)
Tel: +1 310 794 6629; E-mail: [email protected]

PRESS CONTACTS…

For North America and Canada
Katie McGoldrick, Nature Washington
Tel: +1 202 737 2355; E-mail: [email protected]

For Japan, Korea, China, Singapore and Taiwan
Mika Nakano, Nature Tokyo
Tel: +81 3 3267 8751; E-mail: [email protected]

For the UK/Europe/other countries not listed above
Katherine Anderson (Nature London)
Tel: +44 20 7843 4502; E-mail: [email protected]

Ruth Francis (Senior Press Officer, Nature, London)
Tel: +44 20 7843 4562; E-mail: [email protected]

For media inquiries relating to editorial content/policy for Nature Immunology, please contact the journal directly:

Nature Immunology (New York)
Laurie Dempsey
Tel: +1 212 726 9372; E-mail: [email protected]

About Nature Publishing Group

Nature Publishing Group (NPG) is a division of Macmillan Publishers Ltd, dedicated to serving the academic, professional scientific and medical communities. NPG's flagship title, Nature, was first published in 1869. Other publications include Nature research journals, Nature Reviews, Nature Clinical Practice and a range of prestigious academic journals including society-owned publications. NPG also provides news content through [email protected] and scientific career information through Naturejobs.

NPG is a global company with headquarters in London and offices in New York, San Francisco, Washington DC, Boston, Tokyo, Paris, Munich, Hong Kong, Melbourne, Delhi, Mexico City and Basingstoke. For more information, please go to www.nature.com

Published: 02 Feb 2007

Contact details:

The Macmillan Building, 4 Crinan Street
London
N1 9XW
United Kingdom

+44 20 7833 4000
Country: 
Journal:
News topics: 
Content type: 
Websites: 
Reference: 

Nature IMMUNOLOGY